Ajay is an expert in cell-based diagnostic technologies, as well as an experienced entrepreneur, having previously co-founded two life science companies (one acquired in 2012). Ajay received his PhD from the Harvard-MIT Division of Health Sciences and Technology, where he developed a novel platform for circulating tumor cell isolation under the supervision of Mehmet Toner and Daniel Haber at Massachusetts General Hospital.

Bill is a tenured medtech executive with broad experience across finance and general management. Over the past twenty years, Bill was an auditor at KPMG, served in a variety of roles at CareFusion/Becton Dickinson, and most recently led finance at Pfenex Biopharmaceuticals (Nasdaq: PFNX) until its acquisition in late 2020. Notably, in addition to several accounting and finance roles, Bill has operations experience (including serving as VP Global Business Operations, Dispensing Technologies at BD). In these operating roles, Bill has helped secure several large health system technology agreements, led a business model transformation of BD’s Pyxis Enterprise Solution business, managed efforts in the federal government segment, and restructured the product release and product lifecycle management processes.

Henry leads research and development efforts to commercialize the microfluidic deformability cytometry technology. His science and engineering expertise spans microfluidics, cancer biology, image processing, and application proof-of-concept clinical studies. Henry is the co-inventor of the deformability cytometry platform, which has resulted in peer-reviewed publications of the technology, as well an accompanying suite of issued patents. Henry holds a BS in Bioengineering and Biomedical Engineering from the University of California San Diego and a PhD in Biomedical Engineering from the University of California Los Angeles.

Juliet leads the development and execution of strategic regulatory plans, diligence activities, and processes and teams to take products from concept through premarket submissions to commercialization. She has over 25 years of broad experience leading Regulatory Affairs and Quality in the IVD and medical device industry. Juliet holds an MBA from Saint Mary’s College and a BA in Rhetoric from U.C. Berkeley. She is RAC certified through RAPS and is a Certified Manager of Quality/Organizational Excellence through ASQ.

Chris oversees all aspects of Marketing for Cytovale. He brings over 20 years of experience in Marketing, Market Development, Clinical Research, Training and Commercialization. Prior to Cytovale, Chris held marketing roles at EBR Systems (leadless CRT), Ceterix Orthopaedics (meniscal repair, acquired by Smith and Nephew), Ardian (hypertension, acquired by Medtronic) and Johnson and Johnson (vascular). Chris holds a BS and MS in Mechanical Engineering from the University of California at Berkeley and an MBA from the Kellogg School of Management, Northwestern University.

Gina is responsible for driving global sales for Cytovale, with a focus on growing the company’s enterprise, channel and healthcare client bases.   She brings over 22 years of successful sales results and commercial leadership expertise in the biotechnology and pharmaceutical industries. Throughout her career, she has led multiple global product launches, built commercial teams and served in critical collaborative leadership roles where she nurtured key relationships and engendered strategic partnerships that led to significant revenue growth.  Prior to joining Cytovale Gina most recently served as Chief Commercial Officer for Stratify Genomics. She has also held several commercial leadership positions, led commercial learning and development on a global scale and held key marketing positions with Invitae, Genoptix, Hologic, Prometheus Laboratories, Provista Diagnostics, Novartis, Schering-Plough and Pfizer yielding a broad range of experience with all aspects of market development and execution.